Drug Profile
ASN 008
Alternative Names: ASN-008Latest Information Update: 18 Jan 2024
Price :
$50
*
At a glance
- Originator Asana BioSciences
- Developer Asana BioSciences; Libertas Bio
- Class Analgesics; Anti-inflammatories; Antipruritics; Skin disorder therapies; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pruritus
- Discontinued Pain
Most Recent Events
- 28 Dec 2023 TrialSpark completes the phase II trial in Pruritus in USA (Topical) (NCT05870865)
- 29 May 2023 Discontinued - Preclinical for Pain in USA (SC)
- 29 May 2023 Discontinued - Preclinical for Pain in USA (Topical)